From: Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer
Factors | Cohort (N = 48) |
---|---|
Gender | |
 Male | 29 (60%) |
 Female | 19 (40%) |
Age | |
  < 60 y | 15 (31%) |
  > 60 y | 33 (69%) |
MS status | |
 MSI-H | 17 (35%) |
 MSS | 31 (65%) |
Tumor location | |
 Right | 17 (35%) |
 Left | 31 (65%) |
T stage | |
 T2 | 3 (6%) |
 T3 | 23 (48%) |
 T4 | 22 (46%) |
N stage | |
 N0 | 36 (75%) |
 N1-2 | 12 (25%) |
M stage | |
 M0 | 40 (83%) |
 M1 | 8 (17%) |
Stage | |
 I | 3 (6%) |
 II | 30 (63%) |
 III | 8 (17%) |
 IV | 7 (14%) |
Vascular invasion | |
 positive | 10 (21%) |
 negative | 38 (79%) |